NL-OMON51521RecruitingNot Applicable
Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism after Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease Patients? (PREDICT study) - Do Alemtuzumab Levels Predict T cell chimerism after SCT for SCD?
Hematologie0 sites25 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 16 to 64 (—)
Inclusion Criteria
- •o Age 16 years and older
- •o High performance liquid chromatography (HPLC) confirmed diagnoses of SCD (all
- •o Planned for a non-myeloablative MSD transplantation with alemtuzumab/TBI at
- •the Amsterdam UMC
- •o Willing and able to provide written informed consent
Exclusion Criteria
- •- No specific exclusion criteria
Investigators
Similar Trials
Recruiting
Not Applicable
Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?Sickle Cell DiseaseNCT05905770Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)20
Recruiting
Not Applicable
ymfklier alloreactiviteit in niertransplantatie.kidney transplantation/ niertransplantatierejection/ rejectiealloreactivity/ alloreactiviteitlymph nodes/ lymfklierenNL-OMON26812Erasmus Medical Center
Completed
Not Applicable
ymphnodes with and without Alemtuzumab to Measure Broad Alloreactivity against Donor Antigensniertransplantatierejection of kidney allograft10038430NL-OMON42749Interne Geneeskunde, sector Nefrologie en Niertransplantatie100
Not yet recruiting
Unknown
Prevalence of anti-red blood cell alloantibodies in thalassemia patients receiving regular blood transfusionsCTRI/2024/04/066548Sunil Kumar
Recruiting
Phase 2
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell TransplantationAllogeneic Hematopoietic Cell TransplantationNCT05501756Children's Hospital Medical Center, Cincinnati60